Literature DB >> 10377079

Health-related quality of life after angioplasty and stent placement in patients with iliac artery occlusive disease: results of a randomized controlled clinical trial. The Dutch Iliac Stent Trial Study Group.

J L Bosch1, Y van der Graaf, M G Hunink.   

Abstract

BACKGROUND: To assess the quality of life in patients with iliac artery occlusive disease, we compared primary stent placement versus primary angioplasty followed by selective stent placement in a multicenter randomized controlled trial. METHODS AND
RESULTS: Quality-of-life assessments were completed by 254 patients in a telephone interview. Assessment measures consisted of the RAND 36-Item Health Survey 1.0, time tradeoff, standard gamble, rating scale, health utilities index, and EuroQol-5D. The interviews were performed before treatment and after 1, 3, 12, and 24 months. When the 2 treatments were compared, no significant difference was observed (P>0.05). All measurements showed a significant improvement in the quality of life after treatment (P<0.05). The RAND 36-Item Health Survey measures physical functioning, role limitations caused by physical problems, and bodily pain and the EuroQol-5D were the most sensitive to the impact of revascularization.
CONCLUSIONS: Health-related quality of life improves equally after primary stent placement and primary angioplasty with selective stent placement in the treatment of intermittent claudication caused by iliac artery occlusive disease.

Entities:  

Mesh:

Year:  1999        PMID: 10377079     DOI: 10.1161/01.cir.99.24.3155

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication.

Authors:  J L Bosch; M G Hunink
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

2.  Performance of two measures of general health-related quality of life, the EQ-5D and the RAND-36 among critically ill patients.

Authors:  Anne Kaarlola; Ville Pettilä; Pertti Kekki
Journal:  Intensive Care Med       Date:  2004-11-03       Impact factor: 17.440

3.  Percutaneous interventional reconstruction of the iliac arteries: primary and long-term success rate in selected TASC C and D lesions.

Authors:  Jörn O Balzer; Verena Gastinger; Ralf Ritter; Christopher Herzog; Martin G Mack; Thomas Schmitz-Rixen; Thomas J Vogl
Journal:  Eur Radiol       Date:  2005-04-05       Impact factor: 5.315

Review 4.  Assessment of functional status and quality of life in claudication.

Authors:  Ryan J Mays; Ivan P Casserly; Wendy M Kohrt; P Michael Ho; William R Hiatt; Mark R Nehler; Judith G Regensteiner
Journal:  J Vasc Surg       Date:  2011-02-18       Impact factor: 4.268

5.  Angioplasty versus stenting for iliac artery lesions.

Authors:  Hidde Jongsma; Joost Bekken; Ninos Ayez; Cornelis J Hoogewerf; Vincent Van Weel; Bram Fioole
Journal:  Cochrane Database Syst Rev       Date:  2020-12-01

6.  Stenting for peripheral artery disease of the lower extremities: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-09-01

Review 7.  Endovascular stents for intermittent claudication.

Authors:  Paul Bachoo; P A Thorpe; Heather Maxwell; Karen Welch
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 8.  Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammation.

Authors:  Louis L Nguyen
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

Review 9.  Endovascular revascularisation versus conservative management for intermittent claudication.

Authors:  Farzin Fakhry; Hugo Jp Fokkenrood; Sandra Spronk; Joep Aw Teijink; Ellen V Rouwet; M G Myriam Hunink
Journal:  Cochrane Database Syst Rev       Date:  2018-03-08

Review 10.  A review of health utilities using the EQ-5D in studies of cardiovascular disease.

Authors:  Matthew T D Dyer; Kimberley A Goldsmith; Linda S Sharples; Martin J Buxton
Journal:  Health Qual Life Outcomes       Date:  2010-01-28       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.